Back to Agenda
Session 5: Generics for Combination Products: It’s Complicated
Session Chair(s)
Kim Quaintance-Lunn
Vice President, Head of Regulatory Science and Execution
Alexion, United States
Learning Objective :
Speaker(s)
Speaker
Robert A. Lionberger, PhD
FDA, United States
Director, Office of Research and Standards, Office of Generic Drugs, CDER
![Cory Wohlbach](/_Images/member/Generic_Image_Missing-Profile.jpg)
Devices for Drug-Device Combo Products – How Similar is Similar?
Cory Wohlbach
Teva Pharmaceuticals, United States
Global Vice President, Biosimilar Regulatory Affairs
![Kurt R. Karst, JD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Speaker
Kurt R. Karst, JD
Hyman, Phelps & McNamara, PC, United States
Director, Prescription Drugs and Biologics, Corporate Transactions, Enforcement
Have an account?